SecSonar.com

Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Inhibikase Therapeutics, Inc. (IKT) is a Biotechnology company based in US with a market capitalization of $125.3M. Free cash flow was negative at -$27.8M. This page tracks IKT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 15 employees · IPO Dec 23, 2020

Valuation

Valuation & price

$1.73 · as of May 17, 2026 · -19.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.72

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.09$1.75$1.41Jul 25Dec 25Jul 26Jul 7, 25$1.93Jul 9, 25$2.02Jul 11, 25$1.85Jul 15, 25$1.80Jul 17, 25$1.90Jul 21, 25$1.88Jul 23, 25$1.98Jul 25, 25$1.77Jul 29, 25$1.70Jul 31, 25$1.58Aug 4, 25$1.60Aug 6, 25$1.73Aug 11, 25$1.51Aug 13, 25$1.71Aug 15, 25$1.75Aug 19, 25$1.70Aug 21, 25$1.68Aug 25, 25$1.76Aug 27, 25$1.79Aug 29, 25$1.80Sep 3, 25$1.73Sep 5, 25$1.67Sep 9, 25$1.67Sep 11, 25$1.68Sep 16, 25$1.56Sep 18, 25$1.54Sep 22, 25$1.68Sep 24, 25$1.72Sep 26, 25$1.55Sep 30, 25$1.62Oct 2, 25$1.64Oct 6, 25$1.62Oct 8, 25$1.66Oct 10, 25$1.61Oct 14, 25$1.62Oct 16, 25$1.51Oct 21, 25$1.58Oct 23, 25$1.53Oct 27, 25$1.56Oct 29, 25$1.43Oct 31, 25$1.47Nov 4, 25$1.59Nov 6, 25$1.49Nov 10, 25$1.59Nov 12, 25$1.62Nov 14, 25$1.53Nov 18, 25$1.60Nov 20, 25$1.53Nov 25, 25$1.57Nov 28, 25$1.52Dec 2, 25$1.41Dec 4, 25$1.51Dec 8, 25$1.44Dec 10, 25$1.48Dec 12, 25$1.54Dec 16, 25$1.60Dec 18, 25$1.67Dec 22, 25$1.66Dec 24, 25$1.65Dec 29, 25$1.96Jan 2, 26$1.95Jan 6, 26$2.00Jan 8, 26$1.67Jan 12, 26$1.71Jan 14, 26$1.70Jan 16, 26$1.67Jan 21, 26$1.75Jan 23, 26$1.74Jan 27, 26$1.69Jan 29, 26$1.57Feb 2, 26$1.57Feb 4, 26$1.56Feb 9, 26$1.65Feb 11, 26$1.71Feb 13, 26$1.67Feb 18, 26$1.80Feb 20, 26$1.76Feb 24, 26$2.05Feb 26, 26$2.09Mar 2, 26$1.93Mar 4, 26$1.95Mar 6, 26$1.88Mar 10, 26$1.95Mar 12, 26$1.99Mar 17, 26$1.96Mar 19, 26$1.83Mar 23, 26$1.74Mar 25, 26$1.63Mar 27, 26$1.68Mar 31, 26$1.68Apr 2, 26$1.80Apr 7, 26$1.76Apr 9, 26$1.69Apr 13, 26$1.71Apr 15, 26$1.79Apr 17, 26$1.83Apr 22, 26$1.82Apr 24, 26$1.88Apr 28, 26$1.88Apr 30, 26$1.89May 4, 26$1.94May 6, 26$2.01May 8, 26$2.06May 12, 26$1.92May 14, 26$1.86May 18, 26$1.61May 20, 26$1.68May 22, 26$1.69May 28, 26$1.77Jun 1, 26$1.71Jun 3, 26$1.67Jun 5, 26$1.63Jun 9, 26$1.67Jun 11, 26$1.67Jun 15, 26$1.67Jun 17, 26$1.68Jun 22, 26$1.84Jun 24, 26$1.87Jun 26, 26$1.91Jul 2, 26$1.99
$1.4152-week range$2.14
Loading valuation history…

Fundamentals

Key fundamentals

$125.3M

Market cap

—

Revenue growth (YoY)

-5127.8%

Gross margin

-$27.8M

Free cash flow (USD)

-$178.8M

Net debt

Net cash position

41.7%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$967.4KFY 2017$2.1MFY 2018$4.0MFY 2019$1.1MFY 2020$698.5KFY 2021$3.1MFY 2022$123.4KFY 2023$260.5KFY 2024$0.00FY 2025$0.00
$967.4K$0

Free cash flow by year

2016 → 2025

FY 2016$-29.6KFY 2017$-126.4KFY 2018$715.0KFY 2019$-338.3KFY 2020$-1.1MFY 2021$-14.3MFY 2022$-17.6MFY 2023$-18.1MFY 2024$-19.1MFY 2025$-27.8M
-$29.6K-$27.8M

Gross margin by year

2021 → 2023

FY 2021-266.4%FY 202294.5%FY 2023-5127.8%
-266.4%-5127.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 29, 2026Filing
  • 8-K eventEarnings ReleaseMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • 8-K eventPatient EnrollmentApr 7, 2026Filing

Questions

Frequently asked questions

What is Inhibikase Therapeutics, Inc.'s market cap?

Inhibikase Therapeutics, Inc. (IKT) has a market capitalization of $125.3M.

What is IKT's P/E ratio?

A meaningful P/E ratio is not available for IKT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is IKT's price-to-book (P/B) ratio?

IKT trades at 0.72 times book value per share.

Are insiders buying IKT stock?

SEC Form 4 filings show no open-market insider buys at Inhibikase Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

CRDF

Cardiff Oncology, Inc.

$124.8M

MIST

Milestone Pharmaceuticals Inc.

$124.1M

ALPS

Alps Group Inc

$121.8M

KRRO

Korro Bio, Inc.

$129.6M

BDTX

Black Diamond Therapeutics, Inc.

$130.1M

HRTX

Heron Therapeutics, Inc.

$135.1M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.